China Resources Sanjiu Medical & Pharmaceutical (000999): Tasly Pharmaceutical Group delivery completed, further integration of high-quality resources in the industry.

According to the "Transfer Registration Confirmation" issued by China Securities Depository and Clearing Corporation Limited on March 27, 2025, 418,306,002 shares of Tasly Pharmaceutical Group have been transferred to China Resources Sanjiu Medical & Pharmaceutical.

China International Capital CorporationApr 2 10:07

CHINARES PHARMA (03320.HK): China Resources Sanjiu Medical & Pharmaceutical has completed the proposed acquisition of Tasly Pharmaceutical Group.

On March 27, Gelonghui announced that CHINARES PHARMA (03320.HK) stated that China Resources Sanjiu Medical & Pharmaceutical has received a confirmation letter from China Securities Depository and Clearing Corporation Limited on March 27, 2025, confirming that Tasly Pharmaceutical Group's 418,306,002 shares (equivalent to 28% stake in Tasly Pharmaceutical Group as of the date of this announcement) have been transferred. Therefore, as of the date of this announcement, China Resources Sanjiu has completed the acquisition of the proposed 28% stake in Tasly Pharmaceutical Group according to the terms of the stock purchase agreement, and Tasly Pharmaceutical Group has become a non-wholly-owned subsidiary of the company. China Resources Sanjiu will make payments for the proposed acquisition in accordance with the terms of the stock purchase agreement.

Gelonghui FinanceMar 27 19:58

Express News | Tasly Pharmaceutical Group: Control change completed, China Resources Sanjiu Medical & Pharmaceutical becomes the new controlling shareholder.

BreakingsMar 27 19:17

China Resources Sanjiu Medical & Pharmaceutical (000999) 2024 annual report commentary: Strong growth in core business and steady progress in mergers and acquisitions.

Subject: The company announced its 2024 revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 27.617, 3.368, and 3.118 billion yuan, with year-on-year changes of +11.63%, +18.05%, and +15.01%, among which 4Q2.

Huachuang SecuritiesMar 25 07:57

China Resources Sanjiu Medical & Pharmaceutical (000999): The CHC Business shows strong resilience, and the profit capacity improvement maintains high dividends.

In 2024, the company achieved revenue of 27.617 billion yuan, a year-on-year increase of 11.63%; net income attributable to shareholders was 3.368 billion yuan, a year-on-year increase of 18.05%; net income attributable to shareholders after deducting non-recurring gains and losses was 3.118 billion yuan, a year-on-year increase of 1.

China MerchantsMar 24 00:00

Research Reports Gold Digging | Orient: Maintains China Resources Sanjiu Medical & Pharmaceutical "Buy" rating, Target Price 56.81 yuan.

The research report from Orient points out that China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) will have a net income of 3.37 billion yuan in 2024, representing an 18.1% year-on-year increase, while the net income after deducting non-recurring items is expected to be 3.12 billion yuan, with a year-on-year growth of 15%, meeting expectations. The company anticipates that the revenue will achieve double-digit growth in 2025, and net income will match the revenue growth level. In 2024, under the pressure on the retail end of the CHC business, through the concept of "comprehensive layout, leading in all aspects", by enriching the product mix, updating brand communication methods, strengthening channel collaboration, and various other measures, the business is expected to grow by 14.1% year-on-year.

Gelonghui FinanceMar 18 15:00 · Ratings